LLY

1,036.35

+1.36%↑

JNJ

199.78

+0.35%↑

ABBV

234.61

+0.57%↑

UNH

314.19

-2.11%↓

AZN

89.43

+0.25%↑

LLY

1,036.35

+1.36%↑

JNJ

199.78

+0.35%↑

ABBV

234.61

+0.57%↑

UNH

314.19

-2.11%↓

AZN

89.43

+0.25%↑

LLY

1,036.35

+1.36%↑

JNJ

199.78

+0.35%↑

ABBV

234.61

+0.57%↑

UNH

314.19

-2.11%↓

AZN

89.43

+0.25%↑

LLY

1,036.35

+1.36%↑

JNJ

199.78

+0.35%↑

ABBV

234.61

+0.57%↑

UNH

314.19

-2.11%↓

AZN

89.43

+0.25%↑

LLY

1,036.35

+1.36%↑

JNJ

199.78

+0.35%↑

ABBV

234.61

+0.57%↑

UNH

314.19

-2.11%↓

AZN

89.43

+0.25%↑

Search

Crinetics Pharmaceuticals Inc

Aperta

SettoreSettore sanitario

43.11 -0.6

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

42.48

Massimo

43.76

Metriche Chiave

By Trading Economics

Entrata

-14M

-130M

Vendite

-888K

143K

Margine di Profitto

-90,972.727

Dipendenti

437

EBITDA

-12M

-142M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+83.82% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-102M

3.9B

Apertura precedente

43.71

Chiusura precedente

43.11

Notizie sul Sentiment di mercato

By Acuity

57%

43%

315 / 374 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

17 nov 2025, 18:59 UTC

I principali Market Mover

Medicus Pharma Shares Rise After Filing of FDA Priority-Voucher Application

17 nov 2025, 23:40 UTC

Discorsi di Mercato

Gold Consolidates Amid Mixed Signals -- Market Talk

17 nov 2025, 23:34 UTC

Discorsi di Mercato

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

17 nov 2025, 22:58 UTC

Discorsi di Mercato

RBA's Easing Cycle Is Done, TD Securities Says -- Market Talk

17 nov 2025, 22:46 UTC

Discorsi di Mercato

Risk Assets Set to Have a Strong 2026 -- Market Talk

17 nov 2025, 22:06 UTC

Acquisizioni, Fusioni, Takeovers

Constellation Software's Harris Operating Group Completes Agreement To Acquire TECVIA Holding GmbH >CSU.T

17 nov 2025, 22:02 UTC

Utili

Trip.com Group 3Q Rev $2.6B >TCOM

17 nov 2025, 22:02 UTC

Utili

Trip.com Group 3Q Adj EPS $3.87 >TCOM

17 nov 2025, 22:02 UTC

Utili

Trip.com Group 3Q EPS $4.02 >TCOM

17 nov 2025, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

17 nov 2025, 21:40 UTC

Utili

James Hardie Industries 2Q Adj EPS 26c >JHX

17 nov 2025, 21:40 UTC

Utili

James Hardie Industries 2Q Loss/Shr 10c >JHX

17 nov 2025, 21:39 UTC

Utili

James Hardie Industries 2Q Sales $1.29B >JHX

17 nov 2025, 21:38 UTC

Utili
Acquisizioni, Fusioni, Takeovers

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 nov 2025, 21:38 UTC

Utili

XPeng Earnings Beat Wall Street Estimates. Why the Stock Is Falling. -- Barrons.com

17 nov 2025, 21:10 UTC

Utili

XP Inc. 3Q EPS BRL2.47 >XP

17 nov 2025, 21:10 UTC

Utili

XP Inc. 3Q Rev BRL4.67B >XP

17 nov 2025, 20:20 UTC

Discorsi di Mercato

U.S. Natural Gas Retreats on Milder Weather Outlook -- Market Talk

17 nov 2025, 20:12 UTC

Discorsi di Mercato

Easing Underlying Inflation in Canada Seen Leaving Door Open to Rate Cuts Next Year -- Market Talk

17 nov 2025, 20:12 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

17 nov 2025, 20:09 UTC

Discorsi di Mercato

Latest Canadian Inflation Data Supports View BoC is Done Cutting Rates This Cycle -- Market Talk

17 nov 2025, 19:29 UTC

Discorsi di Mercato

Gold Slide Continues to Start Week -- Market Talk

17 nov 2025, 19:16 UTC

Utili
Acquisizioni, Fusioni, Takeovers

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 nov 2025, 18:20 UTC

Acquisizioni, Fusioni, Takeovers

Johnson & Johnson Will Buy Cancer Drugmaker Halda Therapeutics for $3.1 Billion -- Barrons.com

17 nov 2025, 16:45 UTC

Acquisizioni, Fusioni, Takeovers

Oil Giant TotalEnergies Is Betting Big on Electricity -- Update

17 nov 2025, 16:16 UTC

Utili
Acquisizioni, Fusioni, Takeovers

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 nov 2025, 16:15 UTC

Utili

Luckin, a Chinese Challenger to Starbucks, Aims to Return to U.S. Stock Market -- WSJ

17 nov 2025, 15:40 UTC

Acquisizioni, Fusioni, Takeovers

Strategy Is in the Crosshairs of Crypto Investors. It Bought More Bitcoin Anyway. -- Barrons.com

17 nov 2025, 15:22 UTC

Acquisizioni, Fusioni, Takeovers

Alphabet Stock Pops After Berkshire Takes Stake. Why Buffett Might Be Buying. -- Barrons.com

17 nov 2025, 15:19 UTC

Discorsi di Mercato

Deutsche Bank's Strategic Plan Looks a Tad Underwhelming -- Market Talk

Confronto tra pari

Modifica del prezzo

Crinetics Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

83.82% in crescita

Previsioni per 12 mesi

Media 80 USD  83.82%

Alto 108 USD

Basso 45 USD

Basato su 15 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Crinetics Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

15 ratings

14

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

30.39 / 33.46Supporto e resistenza

A breve termine

Weak Bullish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Neutral Evidence

Sentiment

By Acuity

315 / 374 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat